Pearl vs CoverMyMeds
Side-by-side comparison of AI visibility scores, market position, and capabilities
Pearl is a dental AI company with the first FDA-cleared multi-pathology AI for dental radiographs; its Second Opinion platform analyzes X-rays in real time to detect caries, bone loss, and other pathologies; deployed in 120+ countries;
About
Pearl is an artificial intelligence company focused on dental diagnostics, headquartered in Los Angeles, California, and founded in 2019 by Ophir Tanz and Rue Liu. The company develops AI software that analyzes dental radiographs (X-rays) in real time to detect dental pathologies including cavities (caries), bone loss, calculus, periapical lesions, and other conditions. Pearl is notably the first company to receive FDA clearance for AI software capable of detecting multiple pathologies simultaneously in dental X-rays — a regulatory milestone that validates its clinical-grade diagnostic performance. The platform is sold under the brand name Second Opinion and is deployed in dental practices across more than 120 countries.
Largest prior authorization network in the US connecting 75K+ pharmacies, 750K+ providers, and all payers. Columbus OH; acquired by McKesson; available free to providers and pharmacies;
About
CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline the authorization process for prescription medications. Founded in 2008 in Columbus, Ohio, and acquired by McKesson Corporation in 2017, CoverMyMeds processes millions of prior authorization requests annually and has become foundational infrastructure for the US pharmacy and specialty medication market. The platform is available at no cost to providers and pharmacies and is funded through health plan and PBM partnerships.\n\nCoverMyMeds' network effect is central to its value: because the platform is used by the vast majority of pharmacies and a very large share of prescribing providers, payers can reach their entire provider and pharmacy network through a single connection. The platform supports real-time benefit checks that show the formulary status and prior authorization requirements for a drug at the point of prescribing, enabling providers to make more informed prescribing decisions before a patient reaches the pharmacy counter. Automated electronic prior authorization (ePA) workflows reduce approval times from days to hours for eligible drug-payer combinations.\n\nAs part of McKesson, CoverMyMeds has expanded its capabilities to include specialty medication access solutions, patient assistance program enrollment, and medication adherence tools. The company's RxCrossroads subsidiary provides hub services for specialty pharmaceutical manufacturers, creating a comprehensive access ecosystem that spans from initial authorization through patient support and adherence management.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.